Posted by Michael Wonder on 20 Oct 2021
FDA pre-submission for saliva based glucose test to replace invasive finger prick
19 October 2021 - The iQ Group Global, on behalf of its subsidiary, Life Science Biosensor Diagnostics, is pleased to announce that one of its licensees, GBS under license from LSBD, to commercialise its non-invasive, real time glucose salivary test; has filed a pre-submission package with the United States FDA.
The purpose of this pre-submission is to confirm with the FDA the clinical trial design, including trial objectives.
